C. Petropoulos

1.0k total citations
17 papers, 769 citations indexed

About

C. Petropoulos is a scholar working on Virology, Infectious Diseases and Hepatology. According to data from OpenAlex, C. Petropoulos has authored 17 papers receiving a total of 769 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Virology, 10 papers in Infectious Diseases and 4 papers in Hepatology. Recurrent topics in C. Petropoulos's work include HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (9 papers) and HIV/AIDS Research and Interventions (5 papers). C. Petropoulos is often cited by papers focused on HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (9 papers) and HIV/AIDS Research and Interventions (5 papers). C. Petropoulos collaborates with scholars based in United States, Canada and France. C. Petropoulos's co-authors include Neil Parkin, Nicholas S. Hellmann, Jeannette M. Whitcomb, Terri Wrin, Colombe Chappey, Elicia Penuel, Rajiv Dua, Nicholas A. Kartsonis, Joseph K. Wong and Javier Martínez‐Picado and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Cancer Research.

In The Last Decade

C. Petropoulos

17 papers receiving 748 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Petropoulos United States 11 626 555 138 95 83 17 769
Jonathan Toma United States 13 778 1.2× 566 1.0× 175 1.3× 149 1.6× 228 2.7× 21 865
R.J. Tritch United States 8 616 1.0× 506 0.9× 208 1.5× 150 1.6× 75 0.9× 10 752
Elly Baan Netherlands 15 768 1.2× 533 1.0× 115 0.8× 142 1.5× 239 2.9× 21 859
Mia Coetzer United States 16 639 1.0× 440 0.8× 186 1.3× 89 0.9× 194 2.3× 25 788
M. B. Vasudevachari United States 12 693 1.1× 550 1.0× 126 0.9× 196 2.1× 140 1.7× 21 861
Luke C. Swenson Canada 17 690 1.1× 585 1.1× 172 1.2× 144 1.5× 84 1.0× 35 834
Tonie Cilliers United States 14 780 1.2× 508 0.9× 208 1.5× 91 1.0× 285 3.4× 19 854
Rukhsana Rahman United States 9 670 1.1× 508 0.9× 293 2.1× 147 1.5× 222 2.7× 20 849
Betty Willems Belgium 17 660 1.1× 494 0.9× 103 0.7× 160 1.7× 210 2.5× 39 776
Kay Limoli United States 12 1.1k 1.8× 1.1k 1.9× 165 1.2× 152 1.6× 111 1.3× 14 1.2k

Countries citing papers authored by C. Petropoulos

Since Specialization
Citations

This map shows the geographic impact of C. Petropoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Petropoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Petropoulos more than expected).

Fields of papers citing papers by C. Petropoulos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Petropoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Petropoulos. The network helps show where C. Petropoulos may publish in the future.

Co-authorship network of co-authors of C. Petropoulos

This figure shows the co-authorship network connecting the top 25 collaborators of C. Petropoulos. A scholar is included among the top collaborators of C. Petropoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Petropoulos. C. Petropoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Reeves, Jacqueline D., et al.. (2017). Cross-sectional assessment of >20,000 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US. Journal of Hepatology. 66(1). S275–S275. 1 indexed citations
2.
Reeves, Jacqueline D., et al.. (2016). Genotypic and Phenotypic Resistance in Clinical Samples Submitted for HCV NS5B Drug Resistance Testing in the Us. Journal of Hepatology. 64(2). S403–S403. 2 indexed citations
3.
Sperinde, Jeff, Beatrice E. Bachmeier, Ahmed Chenna, et al.. (2016). Abstract P3-07-09: Quantitative p95HER2 protein expression is predictive of trastuzumab response in HER2-positive metastatic breast cancer. Cancer Research. 76(4_Supplement). P3–7. 1 indexed citations
4.
Block, Marc R., Olivier Destaing, C. Petropoulos, et al.. (2015). Integrin-mediated adhesion as self-sustained waves of enzymatic activation. Physical Review E. 92(4). 42704–42704. 4 indexed citations
5.
Hardy, Isabelle, Bluma Brenner, Peter K. Quashie, et al.. (2014). Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. Journal of Antimicrobial Chemotherapy. 70(2). 405–411. 32 indexed citations
6.
Yi, Guohua, Mauro Lapelosa, Thomas M. Mariano, et al.. (2013). Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses. PLoS ONE. 8(9). e72205–e72205. 12 indexed citations
7.
Gilbert, Peter B., Maggie Haitian Wang, Terri Wrin, et al.. (2010). Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV‐1 gp120 Vaccine. The Journal of Infectious Diseases. 202(4). 595–605. 90 indexed citations
8.
Stawiski, Eric, et al.. (2010). 766 VALIDATION OF THE GENESEQ™ HCV NS5B SEQUENCING ASSAY FOR PATIENT-DERIVED HCV SUBTYPES 1A AND 1B. Journal of Hepatology. 52. S298–S298. 2 indexed citations
9.
Dua, Rajiv, et al.. (2009). EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Research and Treatment. 122(3). 685–697. 66 indexed citations
10.
Stranix, Brent R., Baohe Tian, A. Dubois, et al.. (2006). Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor. Antiviral Research. 70(2). 17–20. 6 indexed citations
11.
Poon, Betty, Jeffrey T. Safrit, Harold M. McClure, et al.. (2005). Induction of Humoral Immune Responses following Vaccination with Envelope-Containing, Formaldehyde-Treated, Thermally Inactivated Human Immunodeficiency Virus Type 1. Journal of Virology. 79(8). 4927–4935. 28 indexed citations
12.
Parkin, Neil, et al.. (2004). Natural Variation of Drug Susceptibility in Wild-Type Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy. 48(2). 437–443. 84 indexed citations
13.
Grossman, Zehava, Ellen E. Paxinos, Diana Averbuch, et al.. (2004). Mutation D30N Is Not Preferentially Selected by Human Immunodeficiency Virus Type 1 Subtype C in the Development of Resistance to Nelfinavir. Antimicrobial Agents and Chemotherapy. 48(6). 2159–2165. 87 indexed citations
14.
Chappey, Colombe, et al.. (2003). Polymorphisms in p1-p6/p6* of HIV Type 1 Can Delay Protease Autoprocessing and Increase Drug Susceptibility. AIDS Research and Human Retroviruses. 19(9). 779–784. 10 indexed citations
15.
16.
17.
Martínez‐Picado, Javier, Nicholas A. Kartsonis, George J. Hanna, et al.. (2000). Antiretroviral resistance during successful therapy of HIV type 1 infection. Proceedings of the National Academy of Sciences. 97(20). 10948–10953. 169 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan Toma Breakdown of academic impact, for papers by R.J. Tritch Breakdown of academic impact, for papers by Elly Baan Breakdown of academic impact, for papers by Mia Coetzer Breakdown of academic impact, for papers by M. B. Vasudevachari Breakdown of academic impact, for papers by Luke C. Swenson Breakdown of academic impact, for papers by Tonie Cilliers Breakdown of academic impact, for papers by Rukhsana Rahman Breakdown of academic impact, for papers by Betty Willems Breakdown of academic impact, for papers by Kay Limoli
Rankless by CCL
2026